EXOGENOUS PROTEIN-EXPRESSING MICROORGANISM AND USE THEREOF
Disclosed are a VIP gene expressing microorganism, a composition or a kit for preventing or treating a disorder causing gastrointestinal tract damage comprising the same, and a method for preventing or treating a disorder causing gastrointestinal tract damage using the same.
1 . A recombinant microorganism, comprising a promoter, and a heterologous gene encoding vasoactive intestinal peptide (VIP) operably linked to the promoter, wherein the microorganism belongs to the genus of Lactobacillus.
2 . The microorganism of claim 1 , which is Lactobacillus paracasei, Lactobacillus brevis , or Lactobacillus plantarum.
3 . A recombinant microorganism, comprising a constitutive promoter, and a heterologous gene encoding vasoactive intestinal peptide (VIP) operably linked to the promoter, wherein the microorganism is a lactic acid bacterium.
4 . The microorganism of claim 3 , wherein the constitutive promoter consists of the sequence as set forth in SEQ ID No. 10.
5 . The microorganism of claim 3 , wherein the lactic acid bacterium belongs to the genus of Lactobacillus , or Lactococcus.
6 . The microorganism of claim 5 , wherein the lactic acid bacterium is Lactobacillus paracasei, Lactobacillus brevis, Lactobacillus plantarum , or Lactococcus lactis.
7 . The microorganism of claim 1 , further comprising an operably linked signal sequence between the promoter and the heterologous gene.
8 . The microorganism of claim 7 , wherein the signal sequence encodes a signal peptide consisting of the amino acid sequence as set forth in SEQ ID No. 11.
9 . A composition for preventing or treating a disorder causing gastrointestinal tract damage in human, which comprises a recombinant microorganism comprising a promoter, and a heterologous gene encoding vasoactive intestinal peptide (VIP) operably linked to the promoter, wherein the microorganism is a lactic acid bacterium.
10 . The composition of claim 9 , wherein the disorder causes gastrointestinal tract inflammation.
11 . The composition of claim 10 , wherein the disorder is one or more selected from the group consisting of inflammatory bowel disease (IBD), and colitis.
12 . The composition of claim 11 , wherein the inflammatory bowel disease is ulcerative colitis, or Crohn's disease.
13 . The composition of claim 9 , which is an oral dosage form.
14 . The composition of claim 9 , wherein the lactic acid bacterium belongs to the genus of Lactobacillus , or Lactococcus.
15 . The composition of claim 14 , wherein the lactic acid bacterium is Lactobacillus paracasei, Lactobacillus brevis, Lactobacillus plantarum , or Lactococcus lactis.
16 . The composition of claim 9 , wherein the promoter is a constitutive promoter.
17 . The composition of claim 16 , wherein the constitutive promoter consists of the nucleotide sequence of SEQ ID No. 10.
18 . The composition of claim 9 , wherein the recombinant microorganism further comprises an operably linked signal sequence between the promoter and the heterologous gene.
19 . The composition of claim 18 , wherein the signal sequence encodes a signal peptide consisting of the amino acid sequence of SEQ ID No. 11.
20 . The composition of claim 9 , further comprising a therapeutic agent for treating a disorder causing gastrointestinal tract damage.
21 . (canceled)
22 . (canceled)